Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURO GemCis ± Panitumumab in Metastatic Urothelial Carcinoma (HRAS WT)
DRKS00003516Phase 2Recruiting
- Sponsor
- GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie
- Start
- Apr 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab, gemcitabine, cisplatin in transitional cell carcinoma (TCC), bladder cancer, sponsored by GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie. Started Apr 2012; status: recruiting.
02
Drugs
panitumumabgemcitabinecisplatin
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on DRKS00003516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003516.